Literature DB >> 15108279

Identification of a novel mutation in the coding region of the grey-lethal gene OSTM1 in human malignant infantile osteopetrosis.

Alfredo Ramírez1, Julia Faupel, Ingrid Goebel, Anne Stiller, Susanne Beyer, Christina Stöckle, Carola Hasan, Udo Bode, Uwe Kornak, Christian Kubisch.   

Abstract

Autosomal recessive malignant infantile osteopetrosis (ARO) is characterized by severe osteosclerosis, pathologic fractures, hepatosplenomegaly, and pancytopenia. The pathophysiological basis is inadequate bone resorption due to osteoclast dysfunction. In the majority of cases, mutations in either of two human genes cause this fatal disorder: TCIRG1, encoding a subunit of the osteoclast H(+)-ATPase, and the voltage-gated chloride channel gene CLCN7. We excluded both genes in a small inbred family with malignant infantile osteopetrosis and undertook linkage analysis of several candidate loci that are involved in murine osteopetrosis. A region spanning more than 20 cM between the markers D6S1717 and D6S1608 on chromosome 6q21 was found to be homozygous in the affected child. This locus is syntenic to the genomic region harboring the gene for the osteopetrotic mutant mouse grey-lethal (gl). Recently, mutations in a novel gene of unknown function were described in the grey-lethal mouse and in one human patient. Mutation screening of the grey-lethal gene (OSTM1), revealed a homozygous 2-bp deletion in exon 2 (c.415_416delAG) in the affected child. No mutations could be found in six independent ARO patients who had tested negative for mutations in TCIRG1 and CLCN7. In summary, we describe the identification of a novel mutation in the coding sequence of the human grey-lethal gene, which is the second OSTM1 mutation found in human ARO, confirming the involvement of this gene in the pathogenesis of this severe bone disease. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15108279     DOI: 10.1002/humu.20028

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  13 in total

1.  Fine mapping of bone structure and strength QTLs in heterogeneous stock rat.

Authors:  Imranul Alam; Daniel L Koller; Toni Cañete; Gloria Blázquez; Carme Mont-Cardona; Regina López-Aumatell; Esther Martínez-Membrives; Sira Díaz-Morán; Adolf Tobeña; Alberto Fernández-Teruel; Pernilla Stridh; Margarita Diez; Tomas Olsson; Martina Johannesson; Amelie Baud; Michael J Econs; Tatiana Foroud
Journal:  Bone       Date:  2015-08-19       Impact factor: 4.398

2.  Secretion of a truncated osteopetrosis-associated transmembrane protein 1 (OSTM1) mutant inhibits osteoclastogenesis through down-regulation of the B lymphocyte-induced maturation protein 1 (BLIMP1)-nuclear factor of activated T cells c1 (NFATc1) axis.

Authors:  Bongjin Shin; Jungeun Yu; Eui-Soon Park; Seunga Choi; Jiyeon Yu; Jung Me Hwang; Hyeongseok Yun; Young-Ho Chung; Kwan Soo Hong; Jong-Soon Choi; Masamichi Takami; Jaerang Rho
Journal:  J Biol Chem       Date:  2014-10-30       Impact factor: 5.157

Review 3.  Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

Authors:  T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

Review 4.  Osteopetrosis.

Authors:  Zornitza Stark; Ravi Savarirayan
Journal:  Orphanet J Rare Dis       Date:  2009-02-20       Impact factor: 4.123

5.  OSTM1 regulates beta-catenin/Lef1 interaction and is required for Wnt/beta-catenin signaling.

Authors:  Michael E Feigin; Craig C Malbon
Journal:  Cell Signal       Date:  2008-01-24       Impact factor: 4.315

6.  Brain lipid composition in grey-lethal mutant mouse characterized by severe malignant osteopetrosis.

Authors:  Alessandro Prinetti; Federica Rocchetta; Elvira Costantino; Annalisa Frattini; Elena Caldana; Francesca Rucci; Arianna Bettiga; Pietro L Poliani; Vanna Chigorno; Sandro Sonnino
Journal:  Glycoconj J       Date:  2008-09-10       Impact factor: 2.916

7.  Refined genomic localization of the genetic lesion in the osteopetrosis (op) rat and exclusion of three positional and functional candidate genes, Clcn7, Atp6v0c, and Slc9a3r2.

Authors:  B Perdu; P R Odgren; L Van Wesenbeeck; K Jennes; C C Mackay; W Van Hul
Journal:  Calcif Tissue Int       Date:  2009-03-04       Impact factor: 4.333

8.  Prognostic potential of precise molecular diagnosis of Autosomal Recessive Osteopetrosis with respect to the outcome of bone marrow transplantation.

Authors:  Anna Villa; Alessandra Pangrazio; Elena Caldana; Matteo Guerrini; Paolo Vezzoni; Annalisa Frattini; Cristina Sobacchi
Journal:  Cytotechnology       Date:  2008-09-30       Impact factor: 2.058

9.  Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment.

Authors:  A Del Fattore; B Peruzzi; N Rucci; I Recchia; A Cappariello; M Longo; D Fortunati; P Ballanti; M Iacobini; M Luciani; R Devito; R Pinto; M Caniglia; E Lanino; C Messina; S Cesaro; C Letizia; G Bianchini; H Fryssira; P Grabowski; N Shaw; N Bishop; D Hughes; R P Kapur; H K Datta; A Taranta; R Fornari; S Migliaccio; A Teti
Journal:  J Med Genet       Date:  2005-08-23       Impact factor: 6.318

10.  Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans.

Authors:  Liesbeth Van Wesenbeeck; Paul R Odgren; Fraser P Coxon; Annalisa Frattini; Pierre Moens; Bram Perdu; Carole A MacKay; Els Van Hul; Jean-Pierre Timmermans; Filip Vanhoenacker; Ruben Jacobs; Barbara Peruzzi; Anna Teti; Miep H Helfrich; Michael J Rogers; Anna Villa; Wim Van Hul
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.